Replies to post #73682 on Anavex Life Sciences Corp (AVXL)

[apostrophe]

re: "There was not even a control arm. "

We already know what the industry darling, Aricept/Donepezil does.

http://www.webmd.com/alzheimers/news/20060317/11-aricept-deaths-in-clinical-trial

There is also already decades of data on steady cognitive decline due to AZ with and without various attempted treatments. How many more times do you think that needs to be proven.

[bas2020]

I don't believe you fully understand the purpose of an adaptive open-label trial, which was approved by the FDA. It met its endpoints and the data will enable the company to design a meaningful Phase 3 with a high probability of success.

There is more to this drug (MoA) than just Alzheimer's. Great things are about to happen, including a partner and/or grant.

[apostrophe]

re: "The anecdotal findings are practically meaningless."

They're not anecdotal anymore. They have been duly recorded and reported by trained and certified medical observers in a clinical setting.

[nobrainerstocks]

But it has stabilised the disease at 31 weeks with an excellent safety profile. For that reason alone this should be a bit higher than $3 IMO.